CLAIMS

1- Use of a compound characterized in that it is for the manufacture of a drug for the treatment of chronic kidney disease (CKD), AIDS-associated nephropathy, ischemic nephropathy, tubulointerstitial nephropathy, hydronephrosis, renal dysplasia, medullary sponge kidney, multicystic dysplastic kidney, podocytopathy, kidney papillary necrosis, glomerulonephritis, interstitial nephritis, nephrocalcinosis, nephrosclerosis, Alport's syndrome, Fabry's disease, renal sarcoidosis, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), hypertensive nephrosclerosis, chronic glomerulonephritis, chronic transplant glomerulopathy, chronic interstitial nephritis, Sjogren's syndrome, Alagille syndrome, alpha 1-antitrypsin deficiency, or polycystic kidney disease in a subject, wherein the compound is 4-bromo-5-[4-(2,6-dichloro-benzenesulfonyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid, 4-chloro-5-[4-(2,6-dichloro-benzenesulfonyl)-piperazin-1-yl]-benzofuran-2-carboxylic acid or a pharmaceutically salt thereof.

2- The use according to claim 1, characterized in that the drug is for the treatment of CKD.

3- The use according to claim 1, characterized in that the drug is for the treatment of Alport's syndrome.